To
The Management
Medicines Patent Pool Foundation
Rue de Varembé 7, fifth floor
1202 Geneva
Switzerland

Dear Sirs

KPMG in India was appointed by Medicines Patent Pool Foundation, to estimate the savings accruing by making available low-cost medications by the Generic¹ Manufacturers due to agreements negotiated by the Medicines Patent Pool Foundation (MPP² Agreements). Using the inputs from Medicines Patent Pool Foundation, Generics Manufacturers and publicly available information, KPMG in India has estimated³ savings of $1,233.18 mn and supply of 25.76 mn patients' years' treatment⁴ during the period Jan-2012 to Jun-2019 and creating benefit for an additional 248 cases⁵ where countries received new products through the efforts of Medicines Patent Pool Foundation and MPP Agreements.

For KPMG,

Manpreet Singh | Partner - Sustainability Services

¹ Generic Manufacturers means pharmaceutical companies that have benefitted from MPP's efforts.
² MPP Agreements means various access oriented agreements, including license and sub-license agreements signed by MPP with pharmaceutical companies.
³ The boundary of calculation is limited to ex-company information and patient year calculation as defined by MPP.
⁴ Total Patient year figures includes Hepatitis C drugs where patient years represents patient treatments.
⁵ A Case is the first time each new product is sold in a new country.